The phase II trial of Tetrathiomolybdate (Coprexa) for the treatment of idiopathic pulmonary fibrosis (IPF) was completed last year. We are waiting for Dr. Flaherty to release the results. The word is the results are very good but we will have to wait for the report to see how good. This is another piece of news that could come any day.
from Nov 7/06 PR.... http://www.pipelinereview.com/joomla/content/view/7858/109/ As such, COPREXA(tm) has recently completed a phase II clinical trial for the treatment of refractory idiopathic pulmonary fibrosis (IPF), a fatal respiratory disease. COPREXA(tm) is also in a phase II clinical trial for the treatment of primary biliary cirrhosis (PBC), a fibrotic disease of the hepatic system.
Market Data 
Markets 
AI
